The AhR pathway is accompanied by a decrease in glucagon-like peptide-1 (GLP-1) and Interleukin-22 (IL-22), resulting in changes in the intestinal permeability and lipopolysaccharide in functional gastrointestinal diseases. Here, IL22 is linked to gastrointestinal disease.